Zydus Lifesciences on Tuesday mentioned it has acquired approval from the US well being regulator to market a generic product which is used to deal with myxedema coma. The firm has acquired the ultimate approval for Levothyroxine Sodium for Injection in power of 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial from the US Food and Drug Administration (USFDA), the drug agency mentioned in a press release.
Levothyroxine Sodium Injection is indicated for the therapy of myxedema coma.
Zydus mentioned the drug can be manufactured on the group’s injectable manufacturing facility at Jarod, close to Vadodara (India).
Shares of the corporate had been buying and selling 0.19 per cent up at Rs 483.20 apiece on the BSE.
